AGI to solve disease

A deep-tech start-up incubated and co-developed by the UK Golden Triangle universities (Oxford, Cambridge, and King’s College London) that applies Artificial General Intelligence (causal predictive & generative AI) based on symbolic regression and program synthesis to deliver precision healthcare and predictive medicine at scale.

Hybrid AGI enables scalable predictive Intelligence-as-a-Service

OIA’s vision is a world where Superintelligence is used first and foremost for meaningful purposes. For OIA and world experts in logic and computability, AGI is about ultimate optimal prediction and less about simulating human behaviour, as with chatbots or domestic tasks chore robots.

With more than 100 peer-reviewed papers in some of the most prestigious scientific journals, OIA’s AGI inference engine, is meant to help with the most pressing challenges of the human condition, from antibiotic resistance to chronic inflammation to cancer.

Developed by OIA, Algocyte® is a suite of AGI-driven solutions that enable remote and personal digital endpoints in healthcare pathways from clinic to home and from home to clinic. Algocyte® helps understand the dynamics of health and disease, find prescription gaps, complement at-home therapeutic solutions, enable home-driven precision medicine, and manage remote predictive care.

With two medical device patents granted in the U.S., OIA’s Algocyte® combines biochemistry technology, biomedical imaging, mechatronics, and nanotechnology with AI to learn and build digital blood-based twins based on users’ personal and longitudinal data for remote digital care. A detailed version of the individual’s health current baseline against which to track deviations and test for diagnostic hypotheses—a predictive early detection system based upon our AGI inference engine towards longer and better peoples’ health and lifespan.

23m+

Access to

enriched patient longitudinal records

250K

proprietary

super accurate labelled repository of normal and pathological single-cell images for AI training purposes

100+

published

peer-reviewed papers
validating OIA’s science

Access to

120m+

diagnosis & clinical data points

1tn+

proprietary

mechanistic, explainable, and interpretable computable models and testable scientific hypotheses for disease progression

won

multiple

innovation & AI prizes beating companies such as Microsoft, Accenture, and Etihad in international competitions

Fully sponsored and produced by the highest-impact scientific journal, Nature, this video, based on our peer-reviewed publication in the same journal,  explains OIA’s causal and model-driven approach to Artificial General Intelligence.

Algocyte’s universal input devices

  • Fully end-to-end automated portable lab to monitor people’s health at home, from anaemia to infection to cancer to auto immune diseases

  • Data collection: Capable of ingesting multiple data streams from multiple types of data-generating and testing IoT devices

  • Collects & deals with multiple sources of clinical, biological and lifestyle data cross referencing one against each other

  • An open platform on which commercial & academic solutions can be developed and deployed by software and reagent updates based on light, spectral and immunofluorescence microscopy

  • Automation tools for classification and triaging of users and patients

  • Can enable detection of early signals for better and faster clinical responses

  • Can monitor & learn from users over time to support clinical pathways and predictive medicine

  • Advanced AI-reasoning & predictive capabilities for remote care and precision healthcare

  • Finds prescription gaps to support governments and life science companies to implement predictive population health management strategies

Generative AGI diagnostics

Leading AI-driven solutions built using symbolic regressive and predictive Artificial General Intelligence are causal model-driven.

OIA’s Proprietary technology is based on years of research at Oxford, Cambridge, King’s College London, and the Karolinska Institute, which awards the Nobel Prize in Physiology or Medicine.

Built on 3 key pillars

Algocyte® is an AGI precision diagnostics platform providing proprietary quantitative risk assessment scores

Quantitative Precision

Prediction, Prevention and Early Detection

Professionals can analyse users’ results relative to personalised norms, triage, and flag concerning trends

Individualised Learning and Monitoring

The Algocyte® platform learns from each user based on a digital twin baseline and builds their personal profile allowing forecasting, prediction or diagnosing

Want to find out more?

In our downloadable PDF, we share the in-depth science behind our breakthrough product. Delve into the specifics of our leading precision & predictive platform.